| Alcoa Corporation (AAI) CDI 1:1 FOREIGN EXEMPT NYSE |
Materials |
$2,261 |
Rule 144 Filing
|
28 Aug 2026 8:14AM |
$68.890 |
$55.110 |
fallen by
20%
|
|
| Challenger Limited (CGF) ORDINARY FULLY PAID |
Financials |
$8,013 |
Update - Notification of buy-back - CGF
|
28 Aug 2026 8:14AM |
$9.590 |
$11.860 |
risen by
23.67%
|
|
| Worley Limited (WOR) ORDINARY FULLY PAID |
Industrials |
$4,697 |
Update - Notification of buy-back - WOR
|
28 Aug 2026 8:14AM |
$10.120 |
$9.690 |
fallen by
4.25%
|
|
| Block, Inc. (XYZ) CDI 1:1 FOREIGN EXEMPT NYSE |
Financials |
$3,921 |
Notice of Proposed Sale of Securities
|
28 Aug 2026 8:14AM |
$114.870 |
$105.020 |
fallen by
8.57%
|
|
| Helia Group Limited (HLI) ORDINARY FULLY PAID |
Financials |
$1,447 |
Update - Notification of buy-back - HLI
|
28 Aug 2026 8:13AM |
$5.090 |
$5.320 |
risen by
4.52%
|
|
| Virgin Australia Holdings Limited (VGN) ORDINARY FULLY PAID |
Industrials |
$1,874 |
FY26 Financial Results Investor Presentation
|
28 Aug 2026 8:13AM |
$2.810 |
$2.390 |
fallen by
14.95%
|
|
| Solvar Limited (SVR) ORDINARY FULLY PAID |
Financials |
$260 |
Notification of cessation of securities - SVR
|
28 Aug 2026 8:13AM |
$1.680 |
$1.390 |
fallen by
17.26%
|
|
| Pioneer Minerals Limited (PMM) ORDINARY FULLY PAID |
Materials |
$17 |
Pioneer Strengthens Board with Project Development Expertise
|
28 Aug 2026 8:12AM |
$0.150 |
$0.225 |
risen by
50%
|
|
| Capral Limited (CAA) ORDINARY FULLY PAID |
Materials |
$187 |
Update - Notification of buy-back - CAA
|
28 Aug 2026 8:12AM |
$11.780 |
$11.880 |
risen by
0.85%
|
|
| Australian Finance Group Ltd (AFG) ORDINARY FULLY PAID |
Financials |
$375 |
Update - Notification of buy-back - AFG
|
28 Aug 2026 8:12AM |
$1.590 |
$1.420 |
fallen by
10.69%
|
|
| Virgin Australia Holdings Limited (VGN) ORDINARY FULLY PAID |
Industrials |
$1,874 |
FY26 Financial Results ASX Release
|
28 Aug 2026 8:12AM |
$2.810 |
$2.390 |
fallen by
14.95%
|
|
VGN - Price-sensitive ASX Announcement
Full Release
Key Points
- Underlying EBIT increased 13.4% to $753 million in FY26.
- Underlying NPAT rose 21.9% to $404 million and statutory NPAT increased 4.7% to $501 million.
- The Board declared a fully franked FY26 dividend of 7.6 cents per share, the first since re-listing in 2025.
- Underlying EBIT margin improved by 60 basis points to 12.0% and ROIC rose to 20.1%.
- More than $450 million in gross Transformation Program benefits supported earnings and helped offset inflationary cost pressures.
- Net debt was $1.2 billion at 30 June 2026, with leverage of 0.9x underlying EBITDA and available liquidity of $1.6 billion.
- Operational performance improved, with on-time performance rising to 77.1% and completion rate increasing to 98.7%.
- The Airlines segment delivered underlying EBIT of $616 million, up 15.2%, on underlying revenue of $6.0 billion.
- Velocity delivered underlying EBIT of $143 million, up 12.3%, with external billings up 12.4% and active members up 9%.
- Virgin Australia delivered 17 new aircraft in FY26 and reduced average fleet age to 11.5 years.
- FY27 outlook indicates 1H underlying EBIT is expected to be broadly in line with 1H FY26 based on the forward fuel curve.
- Virgin Australia expects domestic capacity to reduce by 3% in 1H FY27, RASK to grow 6–8%, and FY27 capex to be about $0.9–1.0 billion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Patrys Limited (PAB) ORDINARY FULLY PAID |
Health Care |
$18 |
Ethics Approval Secured for Phase 1A Clinical Trial
|
28 Aug 2026 8:12AM |
$0.030 |
$0.026 |
fallen by
13.33%
|
|
PAB - Price-sensitive ASX Announcement
Full Release
Key Points
- Patrys received Human Research Ethics Committee approval for its Phase 1A clinical trial of RLS-2202.
- The approval was granted by Bellberry on 27 August 2026.
- The Phase 1A bridging study will evaluate the safety, tolerability and pharmacokinetics of RLS-2202 in healthy adult volunteers.
- The trial will be conducted at CMAX in South Australia.
- The study includes intravenous and oral administration of RLS-2202.
- The trial uses a sequential dose-escalation design with oversight from an independent Safety Review Committee.
- Primary focus is safety and tolerability, with secondary objectives including pharmacokinetic profiling and dose selection for future trials.
- Patrys will next complete TGA notification under the CTN Scheme, ANZCTR registration, site initiation, participant screening and enrolment.
- First participant dosing is expected to commence in the current quarter.
- Patrys described the approval as a significant regulatory milestone in the clinical development of RLS-2202.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Zip Co Limited (ZIP) ORDINARY FULLY PAID |
Financials |
$2,118 |
Change in substantial holding
|
28 Aug 2026 8:12AM |
$2.560 |
$1.700 |
fallen by
33.59%
|
|
| Lotus Resources Limited (LOT) ORDINARY FULLY PAID |
Energy |
$104 |
Becoming a substantial holder
|
28 Aug 2026 8:12AM |
$0.265 |
$0.190 |
fallen by
28.30%
|
|
| WAM Capital Limited (WAM) ORDINARY FULLY PAID |
Financials |
$1,148 |
Appendix 4G
|
28 Aug 2026 8:12AM |
$1.510 |
$1.000 |
fallen by
33.77%
|
|
| James Hardie Industries Plc (JHX) CHESS DEPOSITARY INTERESTS 1:1 |
Materials |
$10,839 |
Appendix 3Y - J Singh
|
28 Aug 2026 8:11AM |
$41.740 |
$37.190 |
fallen by
10.90%
|
|
| James Hardie Industries Plc (JHX) CHESS DEPOSITARY INTERESTS 1:1 |
Materials |
$10,839 |
Appendix 3Y - J Singh
|
28 Aug 2026 8:11AM |
$41.740 |
$37.190 |
fallen by
10.90%
|
|
| Lodestar Minerals Limited (LSR) ORDINARY FULLY PAID |
Materials |
$7 |
Drilling Results Strengthen IOCG Model at Three Saints
|
28 Aug 2026 8:11AM |
$0.009 |
$0.005 |
fallen by
44.44%
|
|
LSR - Price-sensitive ASX Announcement
Full Release
Key Points
- Assay results from hole L3SDD004 support the IOCG-style deposit model at the Three Saints Project.
- Copper sulphide mineralisation is closely associated with magnetite and actinolite-biotite alteration within tonalite.
- A skarn-altered interval near the end of hole returned anomalous copper and cobalt, providing a significant exploration vector.
- Reported significant intercepts include 4.30m at 0.12% CuEq from 333.0m and 14.82m at 0.10% CuEq from 404.40m, including 1.0m at 0.43% CuEq.
- The magnetic low anomaly is interpreted to reflect hydrothermal alteration and fault-vein systems linked to IOCG mineralisation.
- The company plans to reprocess geophysical datasets and refine targets focused on extensions of mineralised structures into favourable volcano-sedimentary rocks.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Sea Forest Limited (SEA) ORDINARY FULLY PAID |
Consumer Staple |
$72 |
Appendix 4E and Unaudited Preliminary Financial Report
|
28 Aug 2026 8:11AM |
$1.905 |
$1.530 |
fallen by
19.69%
|
|
SEA - Price-sensitive ASX Announcement
Full Release
Key Points
- Sea Forest Limited reported for the year ended 30 June 2026 under Appendix 4E as an unaudited preliminary final report.
- Revenue from ordinary activities increased 485.5% to $4,983,726.
- All 2026 sales revenue came from SeaFeedâ„¢ sales, with oyster spat activities exited.
- Loss after tax attributable to members improved 40.4% to $5,419,231.
- Total income was $8,449,952, including $2,283,714 of research and development incentive income and $769,270 of interest income.
- There were no government grants recognised in 2026 compared with the prior year.
- Net cash used in operating activities improved to $4,635,616.
- The company invested heavily in term deposits, ending the year with $15,113,104 in term deposits and $12,643,391 in cash and cash equivalents.
- Sea Forest completed its ASX listing on 26 November 2025, raising $20.5 million at $2.00 per share.
- Net financing cash inflow was $18,381,539 after capital raising costs and lease repayments.
- Net assets increased to $39,750,954 from $25,444,746.
- Net tangible assets per ordinary security increased to 70.84 cents from 57.25 cents.
- Property, plant and equipment fell to $12,304,379 after disposals, depreciation and a $296,879 impairment.
- The company sold oyster business assets, the vessel Sea Captain and other marine infrastructure as part of strategic restructuring.
- No dividends were paid, recommended or declared.
- Basic and diluted loss per share improved to 10.4 cents per share.
- The financial report was still in the process of audit at the time of the Appendix 4E release.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| ResMed Inc. (RMD) CDI 10:1 FOREIGN EXEMPT NYSE |
Health Care |
$20,240 |
LR 1.15.3 Compliance
|
28 Aug 2026 8:11AM |
$32.390 |
$35.500 |
risen by
9.60%
|
|
| West Cobar Metals Limited (WC1) ORDINARY FULLY PAID |
Materials |
$5 |
Expansion of Scandium Drilling Targets at Salazar
|
28 Aug 2026 8:11AM |
$0.017 |
$0.013 |
fallen by
23.53%
|
|
WC1 - Price-sensitive ASX Announcement
Full Release
Key Points
- West Cobar Metals plans Q4 2026 air-core drilling at Salazar to test scandium extensions and higher-grade zones.
- The drilling program has been expanded to include the Benriach Prospect as a new scandium target.
- Previous RC drilling at Benriach intersected 27 m at 102 ppm Sc2O3 from 171 m in scandium-enriched amphibolite bedrock.
- Aeromagnetic data define a discrete magnetic body at Benriach where scandium-enriched bedrock may approach the weathered saprolite profile.
- Geochemistry at Benriach indicates an alkaline basalt protolith similar to the bedrock associated with the Newmont saprolite-hosted scandium resource.
- The planned drilling will test whether weathering has produced near-surface scandium enrichment above and adjacent to the Benriach bedrock intersection.
- Salazar already hosts an Inferred scandium Mineral Resource of 15 Mt at 153 ppm Sc2O3 at Newmont.
- Previously reported Newmont intersections indicate potential for higher-grade scandium zones within the existing resource area.
- Metallurgical testwork is progressing alongside drilling to support a low-cost scandium extraction pathway.
- The broader Salazar Project also contains rare earth, titanium, gallium and alumina resources in a large shallow saprolite-hosted system near Esperance in Western Australia.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Percheron Therapeutics Limited (PER) ORDINARY FULLY PAID |
Health Care |
$6 |
Vanderbilt Health to conduct clinical trial of HMBD-002
|
28 Aug 2026 8:11AM |
$0.005 |
$0.003 |
fallen by
40%
|
|
PER - Price-sensitive ASX Announcement
Full Release
Key Points
- Percheron Therapeutics has signed a clinical research agreement with Vanderbilt Health to study HMBD-002 in AML and MDS.
- Vanderbilt Health will lead an investigator-sponsored, multi-centre clinical trial of HMBD-002 combined with standard-of-care treatment.
- The trial is expected to begin start-up activities shortly and aims to commence recruitment in 4Q CY2026.
- Dr Somedeb Ball of Vanderbilt Health will serve as Principal Investigator.
- The proposed study will evaluate HMBD-002 with azacitidine and venetoclax in up to 38 patients with recurrent or newly diagnosed AML/MDS.
- Vanderbilt Health will be primarily responsible for study design, execution and interactions with the US FDA.
- Percheron will provide a financial grant, study drug and technical assistance, and will have full access to the trial data.
- HMBD-002 is a monoclonal antibody targeting the VISTA immune checkpoint regulator.
- Percheron said AML/MDS is a strategic focus for the HMBD-002 program because VISTA is highly expressed in AML and linked to recurrence and therapy resistance.
- Percheron noted that HMBD-002 previously completed a phase I trial in advanced cancer and was reported to be generally safe and well tolerated with signals of potential clinical efficacy.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Temple & Webster Group Ltd (TPW) ORDINARY FULLY PAID |
Consumer Discretionary |
$593 |
Change of Director's Interest Notice - Rowe
|
28 Aug 2026 8:10AM |
$4.620 |
$5.090 |
risen by
10.17%
|
|
| Ramelius Resources Limited (RMS) ORDINARY FULLY PAID |
Materials |
$6,622 |
Update - Notification of buy-back - RMS
|
28 Aug 2026 8:10AM |
$3.910 |
$3.510 |
fallen by
10.23%
|
|
| NewPeak Metals Limited (NPM) ORDINARY FULLY PAID |
Materials |
$4 |
Change in substantial holding
|
28 Aug 2026 8:10AM |
$0.011 |
$0.006 |
fallen by
45.45%
|
|